Evidence map›Paper›PMID 39869459›Full record

ArticleSchizophrenia bulletin2026

Cognitive Impairment in Psychotic Disorders Is Associated with Brain Reductive Stress and Impaired Energy Metabolism as Measured by 31P Magnetic Resonance Spectroscopy.

Virginie-Anne Chouinard, Fei Du, Xi Chen, Emma Tusuzian, Boyu Ren, Jacey Anderson, Kyle Cuklanz, Wirya Feizi, Shuqin Zhou, Akila Weerasekera and 3 more

Abstract read
In one paragraph

Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Virginie-Anne ChouinardPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Fei DuPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Xi ChenPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Emma TusuzianPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Boyu RenDepartment of Psychiatry, Harvard Medical School, Boston, MA, United States.
Jacey AndersonPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Kyle CuklanzPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Wirya FeiziPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Shuqin ZhouPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Akila WeerasekeraPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.ORCID 0000-0003-0446-7604
Bruce M CohenPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Dost ÖngürPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.
Kathryn E LewandowskiPsychotic Disorders Division, McLean Hospital, Belmont, MA, United States.

Funding

Randomized controlled trial of enhanced coordinated specialty care (CSC 2.0)P50MH115846 · NIMH · MCLEAN HOSPITAL · PI MIGUEL HERNAN · 2019 to 2026
$16.9M
Effects of Orally Administered Nicotinamide Riboside on Bioenergetic Metabolism, Oxidative Stress and Cognition in Mild Cognitive Impairment and Mild Alzheimer's DementiaR01AG066670 · NIA · MCLEAN HOSPITAL · PI DU, FEI, FORESTER, BRENT PETER · 2020 to 2024
$4.0M
Molecular Mechanisms of Aging in Schizophrenia: Implications of Bioenergetic Metabolism and Redox BiologyR01MH135093 · NIMH · MCLEAN HOSPITAL · PI FEI DU, Dost Ongur · 2024 to 2026
$2.5M
Molecular Mechanisms and Biomarkers for Disease Progression from Prodrome to Early PsychosisR01MH114982 · NIMH · MCLEAN HOSPITAL · PI DU, FEI, ONGUR, DOST · 2019 to 2023
$2.4M
Neuroprogression across the Psychosis Spectrum in the Early Course of IllnessR01MH117012 · NIMH · MCLEAN HOSPITAL · PI LEWANDOWSKI, KATHRYN EVE · 2019 to 2023
$2.4M
Energy Metabolism Markers of Cognitive Function in Early Psychosis and RiskK23MH121781 · NIMH · MCLEAN HOSPITAL · PI CHOUINARD, VIRGINIE-ANNE · 2019 to 2023
$966k
NIA NIH HHS R01 AG066670NIH HHSNIMH NIH HHS 1K23MH121781NIMH NIH HHS K23 MH121781NIMH NIH HHS P50 MH115846NIMH NIH HHS P50MH115846NIMH NIH HHS R01AG066670NIMH NIH HHS R01 MH114982NIMH NIH HHS R01MH114982NIMH NIH HHS R01 MH117012NIMH NIH HHS R01MH117012NIMH NIH HHS R01 MH135093NIMH NIH HHS R01MH135093
6 · The paper itself

Abstract

background and hypothesisConvergent evidence shows the presence of brain metabolic abnormalities in psychotic disorders. This study examined brain reductive stress and energy metabolism in people with psychotic disorders with impaired or average range cognition. We hypothesized that global cognitive impairment would be associated with greater brain metabolic dysregulation. STUDY

designParticipants with affective and non-affective psychosis (n = 62) were administered the MATRICS Consensus Cognitive Battery (MCCB) and underwent a 31P-magnetic resonance spectroscopy scan at 4T. We used a cluster-analysis approach to identify 2 clusters of participants with and without cognitive dysfunction. We compared clusters on brain redox balance or reductive stress, measured by the ratio of nicotinamide adenine dinucleotide (NAD+) and its reduced form NADH, in addition to creatine kinase (CK) enzymatic activity and pH. STUDY

resultsThe mean (SD) age of participants was 25.1 (6.3) years. The mean NAD+/NADH ratio differed between groups, with lower NAD+/NADH ratio, suggesting more reductive stress, in the impaired cognitive cluster (t = -2.60, P = .01). There was also a significant reduction in CK activity in the impaired cognitive cluster (t = -2.19, P = .03). Intracellular pH did not differ between the 2 cluster groups (t = 1.31, P = .19). The clusters did not significantly differ on severity of mood and psychotic symptomatology or other measures of illness severity.

conclusionsOur results demonstrate that psychotic disorders with greater cognitive impairment have greater brain metabolic dysregulation, with more reductive stress and decrease in energy metabolic rate markers. This provides new evidence for the potential of emerging metabolic therapies to treat cognitive deficits in psychotic disorders.

Indexed as

BrainCognitive DysfunctionEnergy MetabolismNADPsychotic DisordersAdolescentAdultCreatine KinaseFemaleHumansMagnetic Resonance SpectroscopyMaleYoung AdultCreatine KinaseNADbipolar disordercognitive impairmentenergy metabolismmagnetic resonance spectroscopy (MRS)redox balanceschizophrenia

Identifiers

PMID39869459
PMCPMC12996884

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.